West German Study Group

This trial is for people with a specific type of early breast cancer (ER+/HER2-) that is at a high risk of coming back. It will test if starting treatment with a new drug called elacestrant, with or without another standard drug, for 5 years is better at keeping the cancer away t…

This large trial is testing two main ideas for treating aggressive, early-stage triple-negative breast cancer. First, it asks if patients who respond very well to initial chemo can safely skip more of it and go straight to surgery. Second, for patients who don't respond as well, …